SGMO Sangamo Therapeutics
- 0.561
- +0.037+7.11%
Sangamo Therapeutics News
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the e
Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the expected value was -0.21 dollars.
Sangamo Therapeutics | 10-Q: Quarterly report
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results Showcased 20 presentations at the 27(th) American Society of Gene & Cell Therapy (ASGCT) Annual Meetin
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9,
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac
Sangamo Therapeutics Shares Drop 15% After $24M Offering Prices
By Chris Wack Sangamo Therapeutics shares were down 14% to 83 cents after the company entered a securities purchase agreement with institutional investors for the purchase and sale of 24.8 million sh
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the pote
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics with a Buy and raises the price target from $3 to $5.
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says
Sangamo Therapeutics' (SGMO) emphasis remains on progressing neurology programs toward clinical development, Wedbush said in a report Thursday. The company reported Q4 results on Wednesday and provide
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
RBC Capital analyst Luca Issi reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Sector Perform and maintains $2 price target.
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares have been powering on, with a gain of 50% in the last thirty days. But the last month did very little to improve the 6
Analysis
Price Target
No Data
